Non-Hodgkin lymphoma (NHL) is a broad group of blood cancers that develop from lymphocytes. Treatment depends on the specific type of lymphoma, its stage, previous treatments, and how the disease responds to therapy.
For some patients whose lymphoma has returned or stopped responding to standard treatments, CAR-T cell therapy has opened a new treatment pathway. Instead of relying only on chemotherapy or antibodies to attack lymphoma cells, CAR-T therapy uses the patient’s own T cells, which are genetically modified to recognize and attack cancer cells.
China has developed a strong clinical and commercial CAR-T ecosystem, particularly for B-cell non-Hodgkin lymphomas. Several CD19-directed CAR-T therapies are available for approved indications, while hospitals and research centers continue to investigate next-generation CAR-T approaches.
Which types of non-Hodgkin lymphoma can be treated with CAR-T therapy?
CAR-T therapy is not a treatment for every type of non-Hodgkin lymphoma. Its established use is mainly in B-cell lymphomas, where the cancer cells commonly express the CD19 antigen.
Depending on the product and regulatory indication, CAR-T therapy may be considered for diseases such as:
- Diffuse large B-cell lymphoma (DLBCL)
- Other large B-cell lymphomas
- Follicular lymphoma
- Mantle cell lymphoma in selected treatment or clinical-trial settings
- Other relapsed or refractory B-cell lymphomas through clinical trials
The exact indication varies between CAR-T products and countries. A patient’s pathology report, immunophenotyping results, previous treatments, and current disease status all need to be reviewed before treatment is considered.
CD19: a key target in B-cell lymphoma
CD19 is a protein found on the surface of most B cells, including many malignant B cells. This makes it an important target for CAR-T cell therapy.
During treatment, a patient’s T cells are collected and modified so that they carry a chimeric antigen receptor designed to recognize CD19. After the cells are expanded and prepared, they are returned to the patient through an intravenous infusion.
The goal is for the CAR-T cells to recognize CD19-positive lymphoma cells and destroy them.
Several CAR-T products used in China for B-cell lymphoma are CD19-directed. Clinical studies of Chinese products such as relma-cel have demonstrated meaningful responses in heavily pretreated patients with relapsed or refractory large B-cell lymphoma.
When might CAR-T therapy be considered?
CAR-T therapy is generally considered when lymphoma has relapsed or become refractory after previous treatment. For some patients, it can provide an option when conventional therapies are no longer producing adequate disease control.
Whether a patient is eligible depends on more than the diagnosis alone. Doctors may evaluate:
- The exact lymphoma subtype
- CD19 expression and other pathology findings
- Previous chemotherapy, immunotherapy, targeted therapy, or transplant
- Whether the lymphoma is relapsed or refractory
- Disease burden and the location of lymphoma
- Overall physical condition
- Heart, liver, kidney, lung, and blood-cell function
- Active infections or other medical problems
- Previous CAR-T or stem cell transplantation
Treatment decisions are made individually. Having a diagnosis of non-Hodgkin lymphoma does not automatically mean that CAR-T therapy is appropriate.
CAR-T cell therapy for international patients in China
For patients considering treatment in China, the process usually begins before traveling to China.
The medical team needs to review the patient’s records and determine whether CAR-T therapy may be appropriate. Useful documents may include:
- Pathology and immunohistochemistry reports
- PET-CT or CT scans and reports
- Bone marrow examination, when applicable
- Blood test results
- Previous treatment records
- Medication history
- Stem cell transplantation history
- Previous CAR-T treatment, if any
- Current clinical condition
An initial remote review can help determine whether the patient should proceed with an in-person evaluation in China.
For international patients, treatment planning also needs to consider travel, hospitalization, accommodation, interpretation, payment arrangements, and follow-up after returning home.
How CAR-T treatment works
Although individual protocols differ, the treatment pathway generally includes several stages.
1. Medical evaluation
The patient is evaluated by the treating hospital to confirm the diagnosis, assess eligibility, and determine whether an approved CAR-T product or clinical trial is appropriate.
2. T-cell collection
The patient’s blood is processed through leukapheresis, which separates and collects T cells from the blood.
3. CAR-T cell manufacturing
The collected T cells are genetically modified to express the CAR that recognizes the selected cancer target, such as CD19. The cells are then expanded and prepared for infusion.
4. Lymphodepleting chemotherapy
Before CAR-T infusion, patients generally receive chemotherapy to reduce certain immune cells and create an environment that allows the infused CAR-T cells to expand.
5. CAR-T infusion
The prepared CAR-T cells are administered through an intravenous infusion.
6. Close monitoring
The patient is closely monitored for treatment-related complications, particularly during the early period after infusion. Follow-up continues after discharge to evaluate the response and watch for delayed side effects.
What are the possible benefits?
CAR-T therapy can produce deep and durable responses in some patients with relapsed or refractory B-cell lymphoma, including patients who have already received several lines of treatment.
However, responses vary between lymphoma subtypes, products, and individual patients. CAR-T therapy should not be presented as a guaranteed cure.
A patient’s doctor will normally discuss the potential benefits alongside other available options, including salvage therapy, targeted treatments, antibody-based therapies, stem cell transplantation, radiation, or clinical trials.
Side effects and safety
CAR-T cell therapy can cause significant side effects, which is why treatment should be performed in an experienced medical center with appropriate monitoring and emergency support.
The two complications most closely associated with CAR-T therapy are:
Cytokine release syndrome (CRS)
CRS can cause fever, low blood pressure, low oxygen levels, and other inflammatory symptoms. Its severity can range from mild to life-threatening.
Immune effector cell-associated neurotoxicity syndrome (ICANS)
Neurological side effects can include confusion, difficulty speaking, reduced attention, tremors, or seizures in severe cases.
Patients may also experience low blood-cell counts, infections, fatigue, and other complications. The treating team monitors patients closely and provides supportive treatment when needed.
CAR-T therapy in China’s lymphoma treatment landscape
China was an early and active center for CAR-T research and has developed several domestically manufactured products. CD19 CAR-T therapies are now part of the treatment landscape for certain B-cell lymphomas in China. Relma-cel, for example, is approved in China for relapsed/refractory large B-cell lymphoma, and research is also expanding into other lymphoma subtypes and newer CAR designs.
Beyond commercially approved therapies, Chinese hospitals and biotechnology companies are investigating new CAR-T approaches, including dual-target CAR-T, next-generation CD19/CD20 approaches, and other strategies designed to improve persistence, reduce relapse, or broaden the population that may benefit.
This means that international patients may encounter two different pathways in China: an approved commercial CAR-T treatment when they meet the relevant indication, or a clinical trial when an investigational therapy is more appropriate.
Choosing a CAR-T center in China
CAR-T treatment involves much more than the cell infusion itself. For international patients, the experience and resources of the treatment center are particularly important.
When evaluating a hospital, consider:
- Experience treating the specific lymphoma subtype
- Access to an approved CAR-T product or appropriate clinical trials
- Availability of intensive care and emergency support
- Experience managing CRS and ICANS
- Pathology and molecular testing capabilities
- Coordination between hematology, oncology, intensive care, neurology, and other specialties
- Experience treating international patients
- Follow-up arrangements after treatment
The best treatment option is not necessarily the newest CAR-T product. It is the approach that fits the patient’s disease, previous treatment history, health status, and treatment goals.
Preparing for treatment in China
Once a hospital accepts a patient for evaluation or treatment, the next steps may include arranging an appointment, completing additional examinations, confirming the treatment plan, and preparing for hospitalization.
International patients should also plan for the possibility that treatment may require several weeks in China, depending on the manufacturing process, disease status, hospital protocol, and recovery after infusion.
Because CAR-T therapy can cause complications after discharge, patients should not plan an immediate return home simply based on the infusion date. The treating team should determine when it is medically safe to travel.
Is CAR-T therapy right for you?
CAR-T cell therapy has changed the treatment landscape for some patients with difficult-to-treat B-cell non-Hodgkin lymphoma. But eligibility is highly individual, and timing can be important.
For an international patient, the first practical step is usually to have the medical records reviewed by an experienced lymphoma/CAR-T team in China. This can help determine whether an approved CAR-T treatment, another therapy, or a clinical trial may be the most appropriate pathway.
CAR-T therapy is a complex treatment, but for selected patients with relapsed or refractory lymphoma, it can offer an important new opportunity when conventional treatments are no longer working.